4.6 Article

Can Rescaling Dose of Dialysis to Body Surface Area in the HEMO Study Explain the Different Responses to Dose in Women versus Men?

Journal

Publisher

AMER SOC NEPHROLOGY
DOI: 10.2215/CJN.02350310

Keywords

-

Funding

  1. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK)

Ask authors/readers for more resources

Background and objectives: In the Hemodialysis (HEMO) Study, the lower death rate in women but not in men assigned to the higher dose (Kt/V) could have resulted from use of V as the normalizing factor, since women have a lower anthropometric V per unit of surface area (V/SA) than men. Design, setting, participants, & measurements: The effect of Kt/V on mortality was re-examined after normalizing for surface area and expressing dose as surface area normalized standard Kt/V (SAn-stdKt/V). Results: Both men and women in the high-dose group received approximately 16% more dialysis (when expressed as SAn-stdKt/V) than the controls. SAn-stdKt/V clustered into three levels: 2.14/wk for conventional dose women, 2.44/wk for conventional dose men or 2.46/wk for high-dose women, and 2.80/wk for high-dose men. VISA was associated with the effect of dose assignment on the risk of death; above 20 L/m(2), the mortality hazard ratio = 1.23 (0.99 to 1.53); below 20 L/m(2), hazard ratio = 0.78 (0.65 to 0.95), P = 0.002. Within gender, V/SA did not modify the effect of dose on mortality. Conclusions: When normalized to body surface area rather than V, the dose of dialysis in women in the HEMO Study was substantially lower than in men. The lowest surface-area-normalized dose was received by women randomized to the conventional dose arm, possibly explaining the sex-specific response to dialysis dose. Results are consistent with the hypothesis that when dialysis dose is expressed as Kt/V, women, due to their lower V/SA ratio, require a higher amount than men. Clin J Am Soc Nephrol 5: 1628-1636, 2010. doi: 10.2215/CJN.02350310

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Nutrition & Dietetics

Residual Renal Phosphate Clearance in Patients Receiving Hemodialysis or Hemodiafiltration

Jorgen Hegbrant, Amparo Bernat, Domingo Del Castillo, Jose Luis Pizarro, Sonia Caparros, Mariano Gaspar, Carlos Jarava, Giovanni F. M. Strippoli, John T. Daugirdas

Summary: This study aimed to investigate the relationships between residual renal clearance and urine output in hemodialysis and hemodiafiltration patients. The results showed that the residual renal phosphate clearance was approximately 23% higher than residual renal urea clearance in these patients. Furthermore, urine volume was a moderately accurate surrogate for estimating residual renal phosphate clearance, but only when urine volume was above 300 mL/day.

JOURNAL OF RENAL NUTRITION (2023)

Article Urology & Nephrology

Comparison of modeled versus reported phosphate removal and modeled versus postdialysis serum phosphate levels in conventional hemodialysis

John T. Daugirdas

Summary: Predictions of phosphate removal using a 2-pool kinetic model were compared with measured values, and the results showed similarity between the two. This is important for conventional 4-hour dialysis treatments.

SEMINARS IN DIALYSIS (2023)

Article Transplantation

Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis

Phil McEwan, Rebecca Boyce, Juan Jose Garcia Sanchez, C. David Sjostrom, Bergur Stefansson, Stephen Nolan, Ricardo Correa-Rotter, Peter Rossing, Glenn M. Chertow, John J. McMurray, David C. Wheeler, Hiddo J. L. Heerspink

Summary: The DAPA-CKD trial demonstrated that dapagliflozin has significant benefits in patients with chronic kidney disease and albuminuria. Using a Markov model, it was predicted that dapagliflozin treatment would lead to longer time in lower CKD stages, reduced mortality, and fewer complications such as heart failure and kidney function decline.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Article Transplantation

Serum testosterone concentrations and outcomes in hemodialysis patients enrolled in the EVOLVE trial

Erik Nilsson, Peter Stenvinkel, Sai Liu, Margaret R. Stedman, Glenn M. Chertow, Juergen Floege

Summary: Lower free testosterone and higher SHBG in serum are associated with higher risk of death or cardiovascular event in men undergoing chronic hemodialysis.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Article Endocrinology & Metabolism

Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study

Jelle M. Beernink, Frederik Persson, Niels Jongs, Gozewijn D. Laverman, Glenn M. Chertow, John J. V. McMurray, Anna Maria Langkilde, Ricardo Correa-Rotter, Peter Rossing, C. David Sjostrom, Robert D. Toto, David C. Wheeler, Hiddo J. L. Heerspink

Summary: This study aimed to determine whether the benefits of dapagliflozin varied by background glucose-lowering therapy (GLT) in patients with type 2 diabetes and chronic kidney disease (CKD). The results demonstrated consistent effects of dapagliflozin on both primary and secondary endpoints across different baseline GLT classes or combinations. Therefore, dapagliflozin has significant clinical implications in reducing kidney and cardiovascular events.

DIABETES CARE (2023)

Article Medicine, General & Internal

Estimated Effect of Parathyroidectomy on Long-Term Kidney Function in Adults With Primary Hyperparathyroidism

Carolyn D. Seib, Calyani Ganesan, Adam Furst, Alan C. Pao, Glenn M. Chertow, John T. Leppert, Insoo Suh, Maria E. Montez-Rath, Alex H. S. Harris, Amber W. Trickey, Electron Kebebew, Manjula Kurella Tamura

Summary: The effect of parathyroidectomy on long-term kidney function in patients with primary hyperparathyroidism (PHPT) and reduced eGFR was investigated. The study found that parathyroidectomy did not have a significant impact on long-term kidney function in older adults with PHPT.

ANNALS OF INTERNAL MEDICINE (2023)

Article Medicine, General & Internal

Population-Wide Screening for Chronic Kidney Disease A Cost-Effectiveness Analysis

Marika M. Cusick, Rebecca L. Tisdale, Glenn M. Chertow, Douglas K. Owens, Jeremy D. Goldhaber-Fiebert

Summary: Adding SGLT2 inhibitors to CKD screening can be cost-effective, with a one-time screening at age 55 having an ICER of $86,300 per QALY gained, reducing the incidence of kidney failure. Screening every 10 years from age 35 to 75 costs less than $100,000 per QALY gained.

ANNALS OF INTERNAL MEDICINE (2023)

Article Oncology

Groundwater constituents and the incidence of kidney cancer

Simon John Christoph Soerensen, Maria E. Montez-Rath, Iona Cheng, Scarlett Lin Gomez, Debora L. Oh, Christian Jackson, Jinhui Li, David Rehkopf, Glenn M. Chertow, Marvin E. Langston, Calyani Ganesan, Alan C. Pao, Benjamin I. Chung, John T. Leppert

Summary: This study evaluated the association between groundwater exposures and kidney cancer incidence and identified several groundwater constituents associated with kidney cancer. Public health efforts to reduce the burden of kidney cancer should consider groundwater constituents as environmental exposures that may be associated with the incidence of kidney cancer.

CANCER (2023)

Article Health Care Sciences & Services

Deceased Donor Kidney Transplantation for Older Transplant Candidates: A New Microsimulation Model for Determining Risks and Benefits

Matthew B. Kaufmann, Jane C. Tan, Glenn M. Chertow, Jeremy D. Goldhaber-Fiebert

Summary: Under the current US kidney allocation system, older candidates receive a disproportionately small share of deceased donor kidneys. By developing a microsimulation model, we found that older candidates may derive substantial benefits from transplantation with lower quality kidneys.

MEDICAL DECISION MAKING (2023)

Article Transplantation

Vadadustat for treatment of anemia in patients with dialysis-dependent chronic kidney disease receiving peritoneal dialysis

Mark J. Sarnak, Rajiv Agarwal, Neil Boudville, Pradip C. P. Chowdhury, Kai-Uwe Eckardt, Carlos R. Gonzalez, Laura A. Kooienga, Mark J. Koury, Kwabena A. Ntoso, Wenli Luo, Patrick S. Parfrey, Dennis L. Vargo, Wolfgang C. Winkelmayer, Zhiqun Zhang, Glenn M. Chertow

Summary: This study is a post hoc analysis of two global, randomized, sponsor-blind, noninferiority trials evaluating the safety and efficacy of vadadustat compared to darbepoetin alfa in patients receiving peritoneal dialysis. The results demonstrate that vadadustat has comparable cardiovascular safety and hematological efficacy to darbepoetin alfa in this patient population.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

Article Medicine, General & Internal

Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants

Ogo Egbuna, Brandon Zimmerman, George Manos, Anne Fortier, Madalina C. Chirieac, Leslie A. Dakin, David J. Friedman, Kate Bramham, Kirk Campbell, Bertrand Knebelmann, Laura Barisoni, Ronald J. Falk, Debbie S. Gipson, Michael S. Lipkowitz, Akinlolu Ojo, Mark E. Bunnage, Martin R. Pollak, David Altshuler, Glenn M. Chertow

Summary: “This study found that targeted inhibition of APOL1 channel function with inaxaplin can reduce proteinuria in individuals with APOL1 variants and focal segmental glomerulosclerosis. This provides a new option for treating kidney diseases associated with APOL1 variants.”

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Article Cardiac & Cardiovascular Systems

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA-CKD Trial

Glenn M. Chertow, Ricardo Correa-Rotter, Priya Vart, Niels Jongs, John J. V. McMurray, Peter Rossing, Anna Maria Langkilde, C. David Sjostrom, Robert D. Toto, David C. Wheeler, Hiddo J. L. Heerspink

Summary: In the DAPA-CKD trial, dapagliflozin was found to reduce the risk of kidney and cardiovascular events in patients with chronic kidney disease and albuminuria. The treatment effect of dapagliflozin was consistent regardless of baseline cardiovascular medication use.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2023)

Letter Medicine, General & Internal

Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease IN RESPONSE

Meir Schechter, Glenn M. Chertow, Hiddo J. L. Heerspink

ANNALS OF INTERNAL MEDICINE (2023)

Article Health Care Sciences & Services

Market Competition and Anemia Management in the United States Following Dialysis Payment Reform

Anshul Bhatnagar, Vishnupriyadevi Parvathareddy, Wolfgang C. Winkelmayer, Glenn M. Chertow, Kevin F. Erickson

Summary: Whether market competition influences health care provider responses to national reimbursement reforms is unknown. This study aimed to explore the association between market competition and changes in anemia management after the expansion of Medicare's dialysis payment bundle. The results showed that after the reimbursement reform, patients in less competitive areas had slightly more pronounced declines in erythropoiesis-stimulating agent (ESA) dose and less pronounced declines in intravenous iron dose compared to areas with more competition. The likelihoods of hemoglobin <9 g/dL, hospitalization, and mortality did not vary with market competition. Serum ferritin concentrations were higher in less competitive areas.

MEDICAL CARE (2023)

Meeting Abstract Transplantation

REASONS FOR DIALYSIS INITIATION AND SAFETY OF DAPAGLIFLOZIN AMONG DIALYSIS PARTICIPANTS: NEW INSIGHTS FROMDAPA-CKD

Hiddo Lambers Heerspink, David C. Wheeler, Niels Jong, Ricardo Correa-Rotter, Peter Rossing, Ronald Gansevoort, John Mcmurray, Anna Maria Langkilde, Robert Toto, Glenn Chertow

NEPHROLOGY DIALYSIS TRANSPLANTATION (2023)

No Data Available